For example, the identification of fusion genes such as EWSR1-FLI1 in Ewing sarcoma, SYT-SSX in synovial sarcoma, and amplification of MDM2 in liposarcoma have already reshaped classification and guided targeted therapy approaches [34,38,39]. This evidence concerns the gene EWSR1 and synovial sarcoma.